Victoza, a revolutionary new treatment for type 2 diabetes has recently launched by Novo Nordisk, one of the leading healthcare companies in diabetes care. The drug as the first human Glucagon-Like-Peptide-1 (GLP-1) analogue, was approved in Jan 2010 by the Drugs Controller General of India (DCGI) for the treatment of type 2 diabetes in adults.
Victoza has been proven to lower not only blood sugar but also body weight and systolic blood pressure more effectively than other diabetes therapies in people with type 2 diabetes. In addition, Victoza has a low risk of hypoglycaemia (dangerously low blood sugar levels), since Victoza only works when there is excess blood sugar.1-6
“The launch of Victoza means a major advancement in the treatment of type 2 diabetes” says Melvin Dsouza, MD Novo Nordisk India. “India has almost 50.8 million people affected by the disease, of which almost 95% are people with Type 2 diabetes and Victoza can be a significant treatment option for these patients,” he added.
Type 2 diabetes costs in India amount to almost 2.1% of the GDP. The bulk of this cost comes from hospitalisations due to the serious complications of poor blood sugar control. These include heart attack, stroke, blindness, kidney failure and amputation.